Pharming Group N.V. (PHGUF)
OTCMKTS
· Delayed Price · Currency is USD
0.9000
+0.1100 (13.92%)
At close: Mar 13, 2025
Pharming Group Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 297.2 | 245.32 | 205.62 | 198.87 | 212.17 | Upgrade
|
| Revenue Growth (YoY) | 21.15% | 19.30% | 3.40% | -6.27% | 12.03% | Upgrade
|
| Cost of Revenue | 35.4 | 25.21 | 17.56 | 21.14 | 23.54 | Upgrade
|
| Gross Profit | 261.8 | 220.1 | 188.06 | 177.73 | 188.64 | Upgrade
|
| Selling, General & Admin | 184.43 | 175.26 | 127.44 | 90.97 | 75.69 | Upgrade
|
| Research & Development | 83.15 | 68.66 | 52.53 | 65.38 | 38.52 | Upgrade
|
| Other Operating Expenses | -2.18 | -2.07 | -2.28 | -2.62 | -1.83 | Upgrade
|
| Operating Expenses | 265.4 | 241.85 | 177.69 | 153.73 | 112.38 | Upgrade
|
| Operating Income | -3.59 | -21.75 | 10.37 | 24 | 76.26 | Upgrade
|
| Interest Expense | -8.74 | -5.96 | -5.36 | -6.09 | -5.94 | Upgrade
|
| Interest & Investment Income | 4.86 | 3.66 | 0.09 | 0.05 | 0.72 | Upgrade
|
| Earnings From Equity Investments | -1.76 | -0.29 | -1.08 | 0.69 | 0.36 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.99 | -2.97 | 4.4 | 14.84 | -19.23 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.21 | -0.13 | -0.11 | -0.09 | -0.07 | Upgrade
|
| EBT Excluding Unusual Items | -8.46 | -27.45 | 8.31 | 33.4 | 52.08 | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.99 | -0.93 | 11.06 | 0.11 | 0.07 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 21.28 | - | - | - | Upgrade
|
| Asset Writedown | -5.03 | -4.92 | -4.38 | -10.44 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -8.06 | Upgrade
|
| Pretax Income | -8.49 | -12.01 | 14.99 | 23.08 | 44.09 | Upgrade
|
| Income Tax Expense | 3.35 | -1.46 | 1.31 | 7.08 | 6.35 | Upgrade
|
| Net Income | -11.84 | -10.55 | 13.67 | 16 | 37.75 | Upgrade
|
| Net Income to Common | -11.84 | -10.55 | 13.67 | 16 | 37.75 | Upgrade
|
| Net Income Growth | - | - | -14.52% | -57.62% | -6.93% | Upgrade
|
| Shares Outstanding (Basic) | 671 | 657 | 649 | 642 | 636 | Upgrade
|
| Shares Outstanding (Diluted) | 671 | 657 | 707 | 701 | 683 | Upgrade
|
| Shares Change (YoY) | 2.18% | -7.09% | 0.85% | 2.70% | 1.37% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | 0.02 | 0.02 | 0.06 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | 0.02 | 0.02 | 0.05 | Upgrade
|
| EPS Growth | - | - | -17.39% | -58.18% | -9.84% | Upgrade
|
| Free Cash Flow | -2.59 | -18.74 | 21.08 | 27.1 | 78.97 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.03 | 0.03 | 0.04 | 0.12 | Upgrade
|
| Gross Margin | 88.09% | 89.72% | 91.46% | 89.37% | 88.91% | Upgrade
|
| Operating Margin | -1.21% | -8.87% | 5.04% | 12.07% | 35.94% | Upgrade
|
| Profit Margin | -3.98% | -4.30% | 6.65% | 8.04% | 17.79% | Upgrade
|
| Free Cash Flow Margin | -0.87% | -7.64% | 10.25% | 13.63% | 37.22% | Upgrade
|
| EBITDA | 3.22 | -15.29 | 17.13 | 30.39 | 82.54 | Upgrade
|
| EBITDA Margin | 1.08% | -6.23% | 8.33% | 15.28% | 38.90% | Upgrade
|
| D&A For EBITDA | 6.82 | 6.46 | 6.76 | 6.39 | 6.29 | Upgrade
|
| EBIT | -3.59 | -21.75 | 10.37 | 24 | 76.26 | Upgrade
|
| EBIT Margin | -1.21% | -8.87% | 5.04% | 12.07% | 35.94% | Upgrade
|
| Effective Tax Rate | - | - | 8.76% | 30.69% | 14.40% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.